...gnostic Laboratories

...candrou Papamina Ave., 2032 Nicosia
...J.Box 22680, 1523 Nicosia, Cyprus
Tel. +357 22772700, Fax: +357 22772888
Email: info@karaiskakio.org.cy • www.karaiskakio.org.cy

karaiskakio FOUNDATION

Name :			**Visit No. :**202309236
Patient ID :		**Gender/Age :** F /58 yrs	**Visit DateTime :**30/08/2023 00:00
Local Patient No :	**Ref No :** L36834		**Sample Type :**PB
Physician Name :	ORPHANOS GEORGE		**Collected Date Time :**30/08/2023 00:00
Physician Email :			**Physician Fax :**
Hospital/Clinic/Lab	GERMAN ONCOLOGY CENTRE		**Hospital Fax :**25208006

MOLECULAR CANCER PATHOLOGY AND GENETICS

Test Description	Result	Comments / Reference
12613 - Hereditary Cancer Investigation (NGS+Digital MLPA)		
Reason for Referral	Hereditary cancer predisposition investigation	
D001-Digital MLPA Cancer Panel	No copy number aberrations detected	D001 Digital MLPA cancer Panel 1 includes a total number of 690 probes for the detection of copy number alterations in 30 genes involved in hereditary cancer.
RESULTS SUMMARY	NO PATHOGENIC VARIANTS DETECTED	

REMARKS

CLINICAL INFORMATION
Strong family history of cancer.

TEST RESULTS AND INTERPRETATION

VARIANTS OF CLINICAL SIGNIFICANCE
No clinically relevant variants have been detected in the genes tested.

RECOMMENDATIONS - FURTHER TESTING ADVICE
It is possible that this patient has a pathogenic variant outside of the genetic regions or genes analysed. Clinical exome sequencing or high-resolution CGH array with LOH analysis may be able to determine the presence of pathogenic variants that could contribute to the patient's phenotype.

DIGITAL MLPA
NGS based digital MLPA analysis is utilized to detect CNVs in 30 genes associated with hereditary predisposition to breast, ovarian, colorectal, gastric, prostate, pancreatic, endometrial cancer or melanoma. Target genes included in Digital MLPA: APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GREM1, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLE, PTEN, RAD51C, RAD51D SMAD4, STK11, TP53.

Authorised By Paul Costeas (For) Director

Approved Date

(*) The Method is included in the laboratory's scope of accreditation. This is an Electronic Copy

14/11/2023 14:22